Phospho-VDR (Ser208) Antibody

Which kinase is responsible for VDR phosphorylation at Ser208?

Casein kinase II (CK-II) has been identified as the primary kinase responsible for phosphorylating VDR at Ser208. This phosphorylation occurs at the sequence 208EEDSDD, which is a typical CK-II consensus recognition site, and is enhanced by 1,25(OH)₂D . Experimental evidence demonstrates that coexpression of wild-type hVDR and CK-II elicits a dose-dependent enhancement of 1,25(OH)₂D₃-stimulated transcription, and this enhancement is abolished when Ser208 is mutated to glycine or alanine . This indicates that CK-II specifically targets this residue to modulate VDR function .

How should Phospho-VDR (Ser208) Antibody be stored and handled for optimal results?

For long-term storage, Phospho-VDR (Ser208) Antibody should be stored at -20°C for up to one year. For short-term storage and frequent use, it can be kept at 4°C for up to one month. It is crucial to avoid repeated freeze-thaw cycles as this can compromise antibody function . The antibody is typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide . When performing experiments, recommended dilutions vary by application:

These ranges provide starting points and should be optimized for specific experimental conditions .

How does phosphorylation at Ser208 affect VDR interaction with coregulatory proteins?

Phosphorylation of VDR at Ser208 enhances protein-protein interaction between VDR and DRIP205 (a subunit of the vitamin D receptor-interacting protein complex). Studies have shown that treatment with okadaic acid, a phosphatase inhibitor, enhances the response of VDR to 1,25(OH)₂D, not by up-regulating VDR or enhancing VDR-RXR interaction with the VDRE, but by stimulating (3- to 4-fold) the interaction between VDR and DRIP205 . This mechanism explains how phosphorylation can influence transcriptional activity without affecting DNA binding. The phosphorylated form of VDR has greater ability to recruit coactivators, thereby enhancing vitamin D-dependent gene transcription .

Additionally, GSK3 inhibition combined with 1,25D treatment has been shown to increase the association of SRC3 (another key coactivator) with VDR, providing further insight into how phosphorylation state affects coregulator recruitment .

What experimental approaches can effectively validate the specificity of Phospho-VDR (Ser208) Antibody?

Multiple validation approaches should be employed to ensure antibody specificity:

• Phospho-specific ELISA: Comparing reactivity between phosphorylated and non-phosphorylated peptides. A proper validation would show strong signal with the phosphopeptide and minimal reactivity with the non-phosphopeptide .

• Peptide blocking experiments: Western blot or immunofluorescence analyses performed with and without pre-incubation with the phosphopeptide. Specific antibodies will show signal reduction or elimination when blocked with the phosphopeptide .

• Mutational analysis: Using cells expressing wild-type VDR versus S208A/G mutants. The antibody should detect wild-type VDR upon phosphorylation stimulation but not the mutant form .

• Phosphatase treatment: Samples treated with phosphatase prior to analysis should show reduced or eliminated signal compared to untreated samples.

• Stimulation experiments: Using treatments known to induce VDR phosphorylation at Ser208, such as 1,25(OH)₂D treatment, heat shock (for HT29 cells), or GSK3 inhibition combined with 1,25D in certain contexts .

Example validation images typically include phospho-ELISA results, immunofluorescence images with and without peptide blocking, and Western blots of appropriately treated cell lysates .

How can phosphorylation status at Ser208 be manipulated in experimental settings to study VDR function?

Several approaches can be employed to manipulate VDR phosphorylation at Ser208:

• Pharmacological manipulation:

  • CK-II activators/inhibitors: Since CK-II is the primary kinase for Ser208, specific CK-II inhibitors can reduce phosphorylation .

  • Phosphatase inhibitors: Okadaic acid treatment enhances VDR phosphorylation and consequent transcriptional activity .

  • GSK3 inhibition: Combined treatment with GSK3 inhibitors (such as SB415286 or lithium) and 1,25D can increase Ser208 phosphorylation in certain cell contexts .

• Genetic approaches:

  • Site-directed mutagenesis: Creating S208A or S208G phospho-deficient mutants or S208D/E phosphomimetic mutants .

  • Overexpression of CK-II: Transfecting cells with CK-II to enhance phosphorylation .

  • CRISPR/Cas9 genome editing: Creating cell lines with endogenous VDR mutations at Ser208.

• Cellular stimulation:

  • 1,25(OH)₂D treatment: Enhances phosphorylation at Ser208 .

  • Heat shock: In certain cell lines (e.g., HT29), heat shock has been shown to induce VDR phosphorylation .

When designing such experiments, it's crucial to include appropriate controls, such as wild-type VDR, other phosphorylation site mutants that should not affect Ser208 phosphorylation, and treatments that modify other phosphorylation sites but not Ser208.

What is the relationship between GSK3 inhibition, VDR phosphorylation at Ser208, and acute myeloid leukemia (AML) treatment?

Research has revealed an important link between GSK3 inhibition, VDR phosphorylation, and AML treatment responses. GSK3 inhibition sensitizes AML cells to 1,25D-induced differentiation through a mechanism involving VDR phosphorylation . Specifically:

• The combination of GSK3 inhibition (using agents like SB415286 or lithium) and low-dose 1,25D leads to enhanced serine phosphorylation of VDR, particularly at Ser208 .

• This hyperphosphorylation enables increased interaction between VDR and the coactivator SRC3, as demonstrated by both mammalian two-hybrid assays and co-immunoprecipitation studies .

• The enhanced VDR-coactivator interaction results in augmented transcriptional activity and subsequent differentiation of AML cells .

This finding has significant therapeutic implications, suggesting that combinatorial approaches targeting GSK3 and vitamin D signaling might overcome the resistance of AML cells to vitamin D-based differentiation therapies. When investigating this phenomenon, researchers should consider:

• Cell type-specific effects (different AML cell lines may respond differently)

• Dose-dependency of both GSK3 inhibitors and 1,25D

• Temporal dynamics of phosphorylation and subsequent cellular responses

• Downstream gene expression changes resulting from enhanced VDR activity

How do different phosphorylation sites on VDR interact with each other in regulating receptor function?

VDR contains multiple phosphorylation sites that work in concert to fine-tune its activity. Understanding their interactions requires consideration of:

• Ser51 vs. Ser208 phosphorylation: While Ser208 phosphorylation by CK-II enhances coactivator recruitment, Ser51 phosphorylation by protein kinase C-β (PKC-β) appears to play a more fundamental role. Mutation at Ser51 led to decreased transcriptional activity after 1,25(OH)₂D treatment, suggesting this phosphorylation is more critical for VDR function compared to Ser208, which plays a modulatory role .

• Negative regulatory phosphorylation: In contrast to the positive effects of Ser51 and Ser208 phosphorylation, Ser182 phosphorylation by PKA negatively impacts VDR function by decreasing heterodimerization with RXR, resulting in decreased transactivation by 1,25(OH)₂D .

• Cell type-specific phosphorylation patterns: Despite evidence of negative effects of PKA-mediated phosphorylation in some contexts, in rat osteosarcoma cell line UMR-106, PKA activation actually up-regulated VDR and augmented 1,25(OH)₂D-dependent induction of target genes .

• Hierarchical and sequential phosphorylation: Limited research exists on whether phosphorylation at one site influences the likelihood or impact of phosphorylation at other sites. This represents an important area for further investigation using combinations of phospho-specific antibodies and phosphomimetic/phosphodeficient mutants.

The complex interplay between these phosphorylation events likely contributes to the tissue-specific and context-dependent actions of vitamin D. A comprehensive phosphorylation map of VDR under various conditions would significantly advance our understanding of VDR regulation.

What are the optimal experimental conditions for detecting phosphorylated VDR at Ser208 in different cell types?

Detection of phosphorylated VDR at Ser208 requires careful optimization based on cell type and experimental context:

• Cell lysis conditions:

  • Use phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate, and phosphatase inhibitor cocktails) in lysis buffers.

  • Perform lysis quickly at cold temperatures to minimize dephosphorylation.

  • Consider detergent compatibility with planned downstream applications.

• Cell type-specific considerations:

  • A549 cells: These have been successfully used for immunofluorescence analysis of Phospho-VDR (Ser208) .

  • HT29 cells: Heat shock treatment has been shown to induce VDR phosphorylation at Ser208 in these cells .

  • OCI-AML3, HL-60, THP-1, and other AML cell lines: Treatment with combined GSK3 inhibitors and 1,25D enhances Ser208 phosphorylation .

• Treatment conditions to enhance phosphorylation:

  • 1,25D treatment: Typically 5-25 nmol/L depending on experiment .

  • GSK3 inhibitors: SB415286 at 7.5 μmol/L or lithium at 10 mmol/L .

  • Treatment duration optimization is crucial, as phosphorylation may be transient.

• Detection methods and controls:

  • Include positive controls (cells known to express phosphorylated VDR at Ser208).

  • Include negative controls (phospho-deficient mutants or phosphatase-treated samples).

  • For Western blot, consider using gradient gels to better resolve phosphorylated forms.

  • For immunofluorescence, optimization of fixation and permeabilization is critical.

What troubleshooting steps should be taken when Phospho-VDR (Ser208) Antibody fails to detect signal in experiments?

When experiencing detection issues with Phospho-VDR (Ser208) Antibody, consider the following troubleshooting steps:

• Antibody-related issues:

  • Verify antibody integrity (age, storage conditions, freeze-thaw cycles).

  • Optimize antibody concentration using a titration series.

  • Try different antibody lots if available.

  • Confirm antibody reactivity with the specific species being studied (human, mouse, rat).

• Sample preparation issues:

  • Ensure phosphatase inhibitors were properly included in all buffers.

  • Verify total VDR expression using a non-phospho-specific VDR antibody.

  • Consider protein enrichment techniques if VDR expression is low.

  • For nuclear proteins like VDR, confirm proper nuclear extraction procedures.

• Technical optimization:

  • For Western blot: Adjust protein loading, transfer conditions, blocking reagents, and incubation times.

  • For ELISA: Verify coating efficiency, blocking conditions, and consider amplification systems.

  • For IF: Optimize fixation and permeabilization protocols; some fixatives may mask epitopes.

• Biological considerations:

  • Confirm that experimental conditions actually induce Ser208 phosphorylation.

  • Consider cell type-specific differences in VDR expression and phosphorylation.

  • Verify the antibody's ability to recognize the specific VDR isoform expressed in your cells.

• Positive control experiments:

  • Use cells treated with known inducers of Ser208 phosphorylation.

  • Consider using in vitro kinase assays with recombinant VDR and CK-II.

How can researchers effectively distinguish between phosphorylation at different serine residues (Ser51, Ser182, Ser208) in VDR?

Distinguishing between different VDR phosphorylation sites requires careful experimental design:

• Phospho-specific antibodies:

  • Use antibodies specifically targeting each phosphorylation site (e.g., Phospho-VDR (Ser51) Antibody vs. Phospho-VDR (Ser208) Antibody).

  • Validate antibody specificity using phospho-deficient mutants for each site.

  • Perform parallel experiments with each antibody under identical conditions.

• Phosphorylation site mutants:

  • Generate single-site mutants (S51A, S182A, S208A) and multi-site mutants.

  • Compare phosphorylation patterns using general phospho-serine antibodies.

  • Analyze functional outcomes (transcriptional activity, protein interactions) of each mutation.

• Kinase-specific manipulations:

  • Different kinases target different sites: PKC-β phosphorylates Ser51, PKA targets Ser182, and CK-II phosphorylates Ser208 .

  • Use specific kinase inhibitors or activators to selectively modify each site.

  • Combine kinase manipulation with phospho-specific antibody detection.

• Mass spectrometry approaches:

  • Tandem mass spectrometry (MS/MS) can precisely identify and quantify phosphorylation at specific residues .

  • Phosphopeptide enrichment techniques can enhance detection of low-abundance phosphorylation events.

  • Targeted MS approaches can be developed for routine monitoring of specific phosphorylation sites.

• Differential induction conditions:

  • Exploit conditions that preferentially induce phosphorylation at specific sites.

  • For example, PKA activators like parathyroid hormone or cAMP affect Ser182 phosphorylation , while 1,25D treatment or CK-II overexpression increases Ser208 phosphorylation.

How does VDR phosphorylation at Ser208 influence its roles in different pathological contexts beyond AML?

VDR phosphorylation at Ser208 may have significant implications in various disease contexts:

• Cancer biology:

  • In lung adenocarcinoma, VDR expression has been characterized , but the specific role of Ser208 phosphorylation remains to be fully elucidated. The phosphorylation status could potentially influence vitamin D responsiveness and disease progression.

  • For HT29 colon cancer cells, heat shock treatment induces Ser208 phosphorylation , suggesting potential connections to stress response pathways in colorectal cancer.

• Calcium-related disorders:

  • Given VDR's central role in calcium homeostasis , altered phosphorylation could contribute to disorders like osteoporosis, rickets, or hypercalcemia.

  • Research examining phosphorylation status in patient samples with these conditions could provide valuable insights.

• Inflammatory and immune-related diseases:

  • VDR regulates immune cell function, and its phosphorylation status might influence immunomodulatory effects of vitamin D.

  • Examination of Ser208 phosphorylation in autoimmune conditions could reveal novel therapeutic targets.

• Cell differentiation disorders:

  • Beyond AML, VDR's role in cellular differentiation extends to multiple tissues, and Ser208 phosphorylation could be a regulatory checkpoint in differentiation programs.

Future research should systematically investigate Ser208 phosphorylation across these contexts, potentially revealing new therapeutic approaches targeting VDR phosphorylation.

What emerging technologies could enhance our understanding of VDR phosphorylation dynamics in live cells?

Several cutting-edge technologies hold promise for advancing our understanding of VDR phosphorylation dynamics:

• Phospho-specific biosensors:

  • FRET-based biosensors designed to specifically detect VDR phosphorylation at Ser208 could enable real-time monitoring in live cells.

  • These could reveal temporal dynamics and subcellular localization patterns of phosphorylation events.

• CRISPR-based technologies:

  • CRISPR knock-in approaches to tag endogenous VDR with fluorescent proteins while maintaining phosphorylation sites.

  • CRISPRa/CRISPRi systems to manipulate expression of kinases/phosphatases that regulate VDR phosphorylation.

  • Base editing to create precise phospho-mimetic or phospho-deficient mutations in endogenous VDR.

• Single-cell multi-omics approaches:

  • Integration of single-cell transcriptomics with phosphoproteomics to correlate VDR phosphorylation states with gene expression profiles.

  • Mass cytometry (CyTOF) with phospho-specific antibodies to analyze VDR phosphorylation in heterogeneous cell populations.

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize phosphorylated VDR in relation to nuclear architecture and chromatin.

  • Lattice light-sheet microscopy for long-term imaging of phosphorylation dynamics with minimal phototoxicity.

  • Proximity labeling approaches (BioID, TurboID, APEX) to identify proteins interacting with phosphorylated VDR.

• Computational modeling:

  • Systems biology approaches to model kinase-phosphatase networks regulating VDR phosphorylation.

  • Molecular dynamics simulations to predict structural consequences of Ser208 phosphorylation.

What methodological approaches can researchers use to study the interplay between VDR SUMOylation and phosphorylation at Ser208?

Recent research has identified SUMOylation as another post-translational modification affecting VDR function, with K91 being identified as a SUMOylation site . Investigating the interplay between SUMOylation and Ser208 phosphorylation requires specialized approaches:

• Sequential immunoprecipitation strategies:

  • First immunoprecipitation with phospho-specific antibodies followed by Western blotting with SUMO antibodies (or vice versa).

  • Mass spectrometry analysis of immunoprecipitated material to identify co-occurring modifications.

• Mutation-based approaches:

  • Create combination mutants (K91R/S208A, K91R/S208D) to assess functional interdependence.

  • Compare phosphorylation levels in SUMOylation-deficient mutants and SUMOylation levels in phospho-deficient mutants.

• Enzymatic manipulation:

  • Investigate how PIAS4 (SUMO E3 ligase) and SENPs (SUMO-specific proteases) affect VDR phosphorylation at Ser208 .

  • Determine whether CK-II activity influences VDR SUMOylation patterns.

• Functional readouts:

  • Analyze coregulator interactions, chromatin occupancy, and transcriptional activity in the context of both modifications.

  • Assess nuclear matrix association, as PIAS4 has been shown to sequester VDR into specific subnuclear compartments .

• Temporal dynamics:

  • Investigate whether one modification precedes and potentially influences the other.

  • Use inducible systems to temporally control one modification and observe effects on the other.

These approaches would help determine whether the modifications occur independently, sequentially, or competitively, and how they collectively influence VDR function.

How does the methodology for detecting VDR phosphorylation at Ser208 compare with approaches for other phosphorylated nuclear receptors?

Detection methodologies for phosphorylated nuclear receptors share common principles but require receptor-specific optimizations:

Common methodological considerations across nuclear receptors include:

• Extraction protocols that preserve phosphorylation status

• Controls that validate antibody specificity (phosphatase treatment, phospho-deficient mutants)

• Need to correlate phosphorylation with functional outcomes

VDR phosphorylation detection stands out in requiring vitamin D induction protocols and consideration of nuclear localization patterns, whereas some other nuclear receptors (e.g., ERα) have more well-established cytoplasmic-nuclear shuttling that can be used as a functional readout of phosphorylation status.

What are the differences in experimental applications between commercially available Phospho-VDR (Ser208) and Phospho-VDR (Ser51) antibodies?

Both Phospho-VDR (Ser208) and Phospho-VDR (Ser51) antibodies are important tools for studying VDR phosphorylation, but they have distinct characteristics and applications:

Key differences in experimental applications:

• Phosphorylation induction: Different treatments induce phosphorylation at these sites - 1,25D and CK-II activation for Ser208 versus PKC-β activation for Ser51 .

• Functional studies: Ser208 phosphorylation studies focus on coactivator interactions (particularly with DRIP205/SRC3) , while Ser51 studies typically examine fundamental transcriptional activation .

• IHC applications: Phospho-VDR (Ser51) antibody is more commonly used in immunohistochemistry applications , providing advantages for tissue-based studies.

• Relation to disease models: Ser208 phosphorylation has been specifically studied in AML contexts with GSK3 inhibition , while the disease contexts for Ser51 phosphorylation may differ.